We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amedisys (AMED) Q4 Earnings Top Estimates, Margins Decline
Read MoreHide Full Article
Amedisys, Inc. (AMED - Free Report) reported adjusted earnings per share (EPS) of $1.18 for fourth-quarter 2021, down 20.8% from the year-ago figure. The bottom line, however, beat the Zacks Consensus Estimate by 0.9%.
The quarter’s adjustments include contingency accrual, certain COVID-related costs as well as benefits from CARES Act & State COVID-19 grants.
GAAP EPS for the fourth quarter was $1.04, down 23.5% compared with the year-ago $1.36.
Net service revenues grossed $559.3 million, up 1.6% year over year. The top line beat the Zacks Consensus Estimate by 0.7%.
2021 at a Glance
Adjusted EPS for the year was $5.95, down 2.6% from the 2020 levels. The figure also beat the consensus mark by 0.3%.
Full-year 2021 net service revenues totaled $2.21 billion, which improved 6.9% from the previous year. Further, the top line surpassed the Zacks Consensus Estimate by 0.5%.
Segment in Detail
Within the Home Health division, net service revenues totaled $337.3 million in the quarter, reflecting a 2.4% rise year over year. Within this segment, Medicare revenues of $230.1 million improved 0.8% year over year. Non-Medicare revenues increased 6% to $107.2 million.
Within the Hospice division, net service revenues were $204.9 million (up 0.5% year over year), including Medicare revenues of $193.9 million (up 0.2%) and non-Medicare revenues of $11 million (up 5.8%).
At Personal Care, net service revenues totaled $15.1 million, reflecting a decline of 13.2% from the year-ago number. The High Acuity Care segment reported net service revenues of $2 million in the fourth quarter. The Corporate segment did not register any recognizable revenue in the fourth quarter.
Margins
Gross profit for the company declined 0.7% to $242.1 million in the quarter under review. Gross margin contracted 101 basis points (bps) to 43.3%.
Expenses on salaries and benefits rose 5.1% to $125.2 million. Other expenses rose 8.5% to $53.7 million. Adjusted operating profit of $63.2 million reflected a 16.1% decline from the year-ago quarter. Adjusted operating margin contracted 237 bps to 11.3% from the prior-year level.
Liquidity and Cash Position
Amedisys exited 2021 with cash and cash equivalents of $42.7 million compared with $81.8 million at 2020-end. The company's long-term obligations (excluding the current portion) were $432.1 million at the end of 2021, compared with $204.5 million at the end of 2020.
Cumulative net cash provided by operating activities at the end of 2021 was $188.9 million compared with $288.9 million a year ago.
2022 Guidance
Amedisys announced its outlook for 2022.
For full-year 2022, the company anticipates net service revenues in the range of $2.330 billion to $2.365 billion. The Zacks Consensus Estimate for 2022 revenues is pegged at $2.36 billion.
Adjusted EPS is projected in the range of $5.23-$5.45. The Zacks Consensus Estimate for the same is pegged at $5.80.
Our Take
Amedisys ended the fourth quarter with better-than-expected earnings and revenues. The top line registered year-over-year growth on robust performances across the Home Health and Hospice segments. Further, improved revenues from the Medicare and Non-Medicare buoy optimism for the company.
However, a year-over-year decline in Personal Care revenues does not bode well. The contraction of both margins is another downside.
Zacks Rank and Key Picks
Amedisys currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space that have announced their quarterly results are Henry Schein, Inc. (HSIC - Free Report) , GlaxoSmithKline plc (GSK - Free Report) and McKesson Corporation (MCK - Free Report) .
Henry Schein, carrying a Zacks Rank #1 (Strong Buy), reported fourth-quarter 2021 adjusted earnings of $1.07 per share, which beat the Zacks Consensus Estimate by 18.9%. Revenues of $3.33 billion outpaced the consensus mark by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC has gained 35.4% versus the industry’s 7.9% growth in the past year.
GlaxoSmithKline, carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2021 adjusted earnings of 69 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate by 9.5%. Revenues of $13 billion outpaced the consensus mark by 3%.
GlaxoSmithKline has an estimated long-term growth rate of 6.8%. GSK has gained 25.4% compared with the industry’s 15.6% growth in the past year.
McKesson, sporting a Zacks Rank #2, reported third-quarter fiscal 2022 adjusted EPS of $6.15, which beat the Zacks Consensus Estimate of $5.38 per share by 14.3%. Revenues of $68.61 billion surpassed the Zacks Consensus Estimate by 3.2%.
McKesson has a long-term earnings growth rate of 11.8%. MCK has gained 54.1% versus the industry’s 7.9% growth in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amedisys (AMED) Q4 Earnings Top Estimates, Margins Decline
Amedisys, Inc. (AMED - Free Report) reported adjusted earnings per share (EPS) of $1.18 for fourth-quarter 2021, down 20.8% from the year-ago figure. The bottom line, however, beat the Zacks Consensus Estimate by 0.9%.
The quarter’s adjustments include contingency accrual, certain COVID-related costs as well as benefits from CARES Act & State COVID-19 grants.
GAAP EPS for the fourth quarter was $1.04, down 23.5% compared with the year-ago $1.36.
Net service revenues grossed $559.3 million, up 1.6% year over year. The top line beat the Zacks Consensus Estimate by 0.7%.
2021 at a Glance
Adjusted EPS for the year was $5.95, down 2.6% from the 2020 levels. The figure also beat the consensus mark by 0.3%.
Full-year 2021 net service revenues totaled $2.21 billion, which improved 6.9% from the previous year. Further, the top line surpassed the Zacks Consensus Estimate by 0.5%.
Segment in Detail
Within the Home Health division, net service revenues totaled $337.3 million in the quarter, reflecting a 2.4% rise year over year. Within this segment, Medicare revenues of $230.1 million improved 0.8% year over year. Non-Medicare revenues increased 6% to $107.2 million.
Amedisys, Inc. Price, Consensus and EPS Surprise
Amedisys, Inc. price-consensus-eps-surprise-chart | Amedisys, Inc. Quote
Within the Hospice division, net service revenues were $204.9 million (up 0.5% year over year), including Medicare revenues of $193.9 million (up 0.2%) and non-Medicare revenues of $11 million (up 5.8%).
At Personal Care, net service revenues totaled $15.1 million, reflecting a decline of 13.2% from the year-ago number. The High Acuity Care segment reported net service revenues of $2 million in the fourth quarter. The Corporate segment did not register any recognizable revenue in the fourth quarter.
Margins
Gross profit for the company declined 0.7% to $242.1 million in the quarter under review. Gross margin contracted 101 basis points (bps) to 43.3%.
Expenses on salaries and benefits rose 5.1% to $125.2 million. Other expenses rose 8.5% to $53.7 million. Adjusted operating profit of $63.2 million reflected a 16.1% decline from the year-ago quarter. Adjusted operating margin contracted 237 bps to 11.3% from the prior-year level.
Liquidity and Cash Position
Amedisys exited 2021 with cash and cash equivalents of $42.7 million compared with $81.8 million at 2020-end. The company's long-term obligations (excluding the current portion) were $432.1 million at the end of 2021, compared with $204.5 million at the end of 2020.
Cumulative net cash provided by operating activities at the end of 2021 was $188.9 million compared with $288.9 million a year ago.
2022 Guidance
Amedisys announced its outlook for 2022.
For full-year 2022, the company anticipates net service revenues in the range of $2.330 billion to $2.365 billion. The Zacks Consensus Estimate for 2022 revenues is pegged at $2.36 billion.
Adjusted EPS is projected in the range of $5.23-$5.45. The Zacks Consensus Estimate for the same is pegged at $5.80.
Our Take
Amedisys ended the fourth quarter with better-than-expected earnings and revenues. The top line registered year-over-year growth on robust performances across the Home Health and Hospice segments. Further, improved revenues from the Medicare and Non-Medicare buoy optimism for the company.
However, a year-over-year decline in Personal Care revenues does not bode well. The contraction of both margins is another downside.
Zacks Rank and Key Picks
Amedisys currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space that have announced their quarterly results are Henry Schein, Inc. (HSIC - Free Report) , GlaxoSmithKline plc (GSK - Free Report) and McKesson Corporation (MCK - Free Report) .
Henry Schein, carrying a Zacks Rank #1 (Strong Buy), reported fourth-quarter 2021 adjusted earnings of $1.07 per share, which beat the Zacks Consensus Estimate by 18.9%. Revenues of $3.33 billion outpaced the consensus mark by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC has gained 35.4% versus the industry’s 7.9% growth in the past year.
GlaxoSmithKline, carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2021 adjusted earnings of 69 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate by 9.5%. Revenues of $13 billion outpaced the consensus mark by 3%.
GlaxoSmithKline has an estimated long-term growth rate of 6.8%. GSK has gained 25.4% compared with the industry’s 15.6% growth in the past year.
McKesson, sporting a Zacks Rank #2, reported third-quarter fiscal 2022 adjusted EPS of $6.15, which beat the Zacks Consensus Estimate of $5.38 per share by 14.3%. Revenues of $68.61 billion surpassed the Zacks Consensus Estimate by 3.2%.
McKesson has a long-term earnings growth rate of 11.8%. MCK has gained 54.1% versus the industry’s 7.9% growth in the past year.